Seasonal COVID-19 vaccination in 2025/26 reduced risk of illness by half in Canada

Novel_Coronavirus_SARS-Cov-2_(50011008502)

Source: NIAID

An interim analysis estimates that the COVID-19 vaccine for the 2025/26 season reduced the risk of illness in Canada by about half at about 9 weeks after vaccination, offering protection beyond the vaccine’s target strain.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE